FLYTE Bio
Start a project

About

I build the AI tools biotech operators wish existed.

One operator. Real biotech context. Software that ships in weeks, not quarters.

Short bio

Jeff Martin

Founder, FLYTE Bio

I'm Jeff Martin. I build custom AI tools, agents, and portals for biotech under the FLYTE Bio brand — from internal dashboards your team uses every morning to branded portals you ship to your customers.

Placeholder for Jeff
4–6 sentences on your background. Why biotech. Anything from your professional history that matters: prior roles, education, time in industry, why you ended up here. Specifics beat adjectives.

The short version of why I do this: biotech operations are still pre-Affinity-era. Fundraising, BD, IND prep, regulatory tracking — most teams run on Excel, Gmail, and memory. Meanwhile Claude is finally good enough to actually run workflows. The gap between "what's now possible" and "what biotech ops teams actually use" is enormous, and closing fast. I'm here because the next 24 months are when most of that closes.

Background

Specifics, not adjectives.

  • Now

    FLYTE Bio

    Custom AI tools, agents, and portals for biotech. Shipped FLYTE Deck for a preclinical biotech in 7 days — a multi-tenant fundraise OS with a 21-tool Claude operator.

  • Earlier

    FLYTE Intelligence / Houston

    AI intelligence pipeline ranking biotech signals daily for a roster of clients. Same architectural pattern that powers FLYTE Deck's morning sync.

  • Placeholder

    [Prior role / education]

    Add 1–2 lines of biotech or technical credibility relevant to the buyer.

The thesis

What I believe about biotech ops + AI + the next five years.

  1. 01

    Claude is finally good enough to operate, not just answer.

    Sonnet 4.6 and Opus 4.7 with tool use, MCP, and adaptive thinking can run real workflows. They call the tools, update the database, draft the email, follow up the next morning. The 'AI assistant that lives in a sidebar' era is over. The 'AI operator that's a peer to your dashboard' era is here.

  2. 02

    Biotech operations are uniquely under-tooled.

    Series A biotechs run their fundraise, BD, regulatory tracking, and clinical operations on spreadsheets and inboxes. Affinity helps the few that adopt it. Veeva and Benchling cover the lab side. Almost nothing covers the operator side — the CFO, COO, Chief of Staff who is actually deciding things and doesn't have a tool that thinks with them.

  3. 03

    The right unit is custom, not SaaS.

    Biotech workflows are specific. The CFO's job is not the COO's job is not the Chief of Staff's job, and a one-size-fits-all SaaS will always lose to a tool built for the exact loop that team runs. Custom used to be too expensive to be worth it. With Claude in the loop, custom now ships in weeks for the cost of a single SaaS year.

  4. 04

    Ownership matters more than people think.

    Biotechs get acquired, restructured, spun out, partnered. The tools they rely on follow them — or don't. A SaaS subscription gets cancelled in a transition; a custom tool you own does not. The ownership isn't a marketing point, it's how the tool survives the next two years of a biotech's life.

How I work

For the buyer who's been burned.

  • 1

    One operator, no offshore team.

    When you talk to me, you're talking to whoever is writing the code.

  • 2

    Weekly demos, not monthly status.

    You see the build advance every Friday or you can fire me.

  • 3

    Direct.

    I'll tell you when I think a feature is a bad idea. I'll also tell you when I'm wrong about that.

  • 4

    No 40-slide decks.

    The output is software, not strategy.

Want to talk?

If you're a biotech operator with a workflow you wish was a tool, tell me about it. I respond within a day.

Start a project →Or email me directly: jeff@flyte.bio →